The Bleeding With Antithrombotic Therapy Study 2

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the incidence and severity of bleeding complications in patients with cerebrovascular and cardiovascular diseases treated with oral antithrombotic therapy.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cerebral and Cardiovascular Center
• Collaborator: Japan Agency for Medical Research and Development
• Treatments: Anticoagulants

Criteria

Inclusion Criteria:

• Patients with cerebrovascular or cardiovascular diseases who start or continue taking oral antithrombotics (antiplatelets and/or anticoagulants) to prevent vascular events

• Patients who are able to receive MRI

• Provision of written informed consent either directly or by a suitable surrogate

Exclusion Criteria:

• MRI contraindication

• Any condition that in the opinion of the responsible physician or investigator that renders the patient unsuitable for the study